2009年甲型H1N1流感灭活裂解疫苗免疫后血凝素特异性CD4+ T细胞应答研究
在两项临床试验中,纵向观察到2009年甲型H1N1流感灭活裂解疫苗两剂接种后,所有受试者均产生强抗体应答;虽未检出针对已知表位的CD8+ T细胞应答,但疫苗可诱导血凝素特异性T细胞应答,且主要为CD4+ T细胞依赖;该应答在接种后6周降至基线,而抗体高水平维持4个月,且T细胞应答强度与血凝抑制抗体滴度显著相关。
要点
- 2009年甲型H1N1流感灭活裂解疫苗两剂接种后,所有受试者均产生强抗体应答。
- 疫苗可诱导血凝素特异性CD4+ T细胞应答,但未检出针对已知表位的CD8+ T细胞应答。
- 血凝素特异性T细胞应答在接种后6周降至基线,抗体高水平维持4个月。
核心结论
- 2009年甲型H1N1流感灭活裂解疫苗可诱导血凝素特异性CD4+ T细胞应答,该应答可能与抗体保护的产生协同作用。
研究设计与样本
- 在两项临床试验中,对受试者接种两剂2009年甲型H1N1流感灭活裂解疫苗前、中、后,纵向研究针对流感病毒已知HLA-I限制性表位及血凝素蛋白的特异性T细胞应答。
主要发现
- 所有受试者接种疫苗后均产生强抗体应答。
- 未检测到针对已知表位的CD8+ T细胞应答,但接种后诱导了血凝素特异性T细胞应答,且该应答主要为CD4+ T细胞依赖。
- 外周血中血凝素特异性T细胞在接种后6周降至基线水平,而体液免疫应答在接种后4个月维持高水平。
- 血凝素特异性T细胞应答强度与血凝抑制抗体滴度呈显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Influenza A virus remains a major threat to public health, and the inactivated split-virus vaccine is the most prevalent vaccine used worldwide. However, our knowledge about cellular immune responses to the inactivated influenza virus vaccine and its correlation with humoral responses are yet limited, which has restricted our understanding of the vaccine's protective mechanisms. Herein, in two clinical trials, T-cell responses specific for both previously identified human leucocyte antigen (HLA)-I-restricted epitopes from influenza virus and hemagglutinin (HA) protein were longitudinally investigated before, during, and after a two-dose vaccination with the inactivated 2009 pandemic H1N1 (2009-pH1N1) vaccine. A robust antibody response in all of the donors after vaccination was observed. Though no CD8+ T-cell responses to known epitopes were detected, HA-specific T-cell responses were primed following vaccination, and the responses were found to be mainly CD4+ T-cell dependent. However, HA-specific T-cells circulating in peripheral blood dropped to baseline levels 6weeks after vaccination, but humoral immune responses maintained a high level for 4months post-vaccination. Significant correlations between the magnitude of the HA-specific T-cell responses and hemagglutination inhibition antibody titers were demonstrated, indicating a priming role of HA-specific T-cells for humoral immune responses. In conclusion, our study indicates that HA-specific CD4+ T-cell responses can be primed by the inactivated 2009-pH1N1 vaccine, which may coordinate with the elicitation of antibody protection. These findings would benefit a better understanding of the immune protective mechanisms of the widely used inactivated 2009-pH1N1 vaccine.
引用
- Tan S, Zhang S, Wu B, et al. Hemagglutinin-specific CD4+ T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans. Vaccine. 2017. PMID: 28917539. doi:10.1016/j.vaccine.2017.08.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。